Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Core Viewpoint - Pyxis Oncology is prioritizing its lead asset, PYX-201, a novel antibody-drug conjugate (ADC) targeting difficult-to-treat cancers, particularly head and neck squamous cell carcinoma (HNSCC) [1][8] Group 1: PYX-201 Development - PYX-201 has shown significant RECIST responses in HNSCC, with a confirmed 50% objective response rate (ORR) in a Phase 1 trial [2] - The drug achieved a disease control rate (DCR) of 100% in a small cohort of heavily pretreated patients [2] - Across six solid tumor types, PYX-201 achieved a 26% ORR, indicating potential for further development in both monotherapy and combination therapy settings [3] Group 2: Clinical Trials and Future Plans - The company plans to initiate patient dosing for both monotherapy and combination therapy trials in early 2025, including a frontline HNSCC study in combination with pembrolizumab [3][4] - Preliminary data from ongoing dose expansion studies is expected in the second half of 2025 and the first half of 2026 [4] Group 3: Financial Outlook - The current cash position is projected to fund the development of PYX-201 into the second half of 2026 [9] Group 4: Pipeline Prioritization - The company has deprioritized its second clinical program, PYX-106, to focus resources on advancing PYX-201 [6][8] - PYX-106 was observed to be generally safe and well-tolerated, but further clinical investment has been suspended [7][8]